Key result
COVID-19 mRNA vaccines linked to ~25 acute myocarditis cases per million, predominantly in young males.
Why the study?
Concerns regarding the rare side effect of acute myocarditis have hindered COVID-19 immunization efforts.
What is the incidence, mechanism, and clinical management of acute myocarditis following COVID-19 vaccination?
What is the incidence, mechanism, and clinical management of acute myocarditis following COVID-19 vaccination?
COVID-19 vaccine-associated myocarditis is a rare, typically mild and self-limited complication primarily affecting young males, and the overall benefits of vaccination far outweigh this risk.
Answers are grounded in this paper and cite their sources.
Supports vigilant post-vaccination monitoring in young males; leaves open mechanistic and long-term outcome questions.
INTRODUCTION: Vaccines have demonstrated protection against the morbidity and mortality of COVID-19, but concerns regarding the rare side effect of acute myocarditis have stymied immunization efforts. This review aims to describe the incidence and theorized mechanisms of COVID vaccine-associated myocarditis and review relevant principles for management of vaccine-associated myocarditis. AREAS COVERED: Epidemiologic studies of myocarditis after COVID vaccination are reviewed, which show an incidence of approximately 20-30 per million patients. The vast majority of these cases are seen with mRNA vaccines especially in male patients under 30 years of age. Mechanisms are largely theoretical, but molecular mimicry and dysregulated innate immune reactions have been proposed. While studies suggest that this subtype of myocarditis is mild and self-limited, long-term evidence is lacking. Principles of myocarditis treatment and surveillance are outlined as they apply to COVID vaccine-associated myocarditis. EXPERT OPINION: COVID vaccine-associated myocarditis is rare but well described in certain at-risk groups. Better understanding of its pathogenesis is key to mitigating this complication and advancing vaccination efforts. Risk-benefit analyses demonstrate that individual- and population-level benefits of vaccination exceed the risks of this rare and mild form of myocarditis.
No takes yet. Share an insight, caveat, or question.
Power et al. (2022) conducted a review in COVID-19 vaccine-associated myocarditis. COVID-19 mRNA vaccines was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: